PTPI
Income statement / Annual
Last year (2023), Petros Pharmaceuticals, Inc.'s total revenue was $5.82 M,
a decrease of 2.83% from the previous year.
In 2023, Petros Pharmaceuticals, Inc.'s net income was -$8.16 M.
See Petros Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$5.82 M
|
$5.99 M
|
$7.81 M
|
$9.56 M
|
$15.58 M
|
$14.05 M
|
| Cost of Revenue |
$1.63 M |
$2.29 M |
$1.60 M |
$4.05 M |
$7.43 M |
$10.48 M |
| Gross Profit |
$4.19 M |
$3.70 M |
$6.21 M |
$5.51 M |
$8.15 M |
$3.57 M |
| Gross Profit Ratio |
0.72 |
0.62 |
0.8 |
0.58 |
0.52 |
0.25 |
| Research and Development
Expenses |
$2.41 M
|
$1.74 M
|
$1.79 M
|
$459,636.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$11.26 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$41,151.00
|
| Selling, General &
Administrative Expenses |
$9.26 M
|
$12.21 M
|
$15.59 M
|
$15.67 M
|
$19.73 M
|
$11.22 M
|
| Other Expenses |
$6.14 M |
$5.60 M |
$6.88 M |
$6.66 M |
$5.29 M |
$0.00 |
| Operating Expenses |
$17.81 M |
$19.55 M |
$24.26 M |
$22.80 M |
$25.02 M |
$11.22 M |
| Cost And Expenses |
$19.44 M |
$21.84 M |
$25.86 M |
$26.84 M |
$32.45 M |
$21.70 M |
| Interest Income |
$515,311.00 |
$14,194.00 |
$368,660.00 |
$3.05 M |
$13.84 M |
$11.86 M |
| Interest Expense |
$536,138.00 |
$596,018.00 |
$368,660.00 |
$3.05 M |
$13.84 M |
$0.00 |
| Depreciation &
Amortization |
$3.42 M
|
$5.72 M
|
$6.98 M
|
$6.75 M
|
$5.32 M
|
$8.06 M
|
| EBITDA |
-$4.21 M
|
-$13.73 M
|
-$1.64 M
|
-$12.21 M
|
-$14.00 M
|
$373,576.00
|
| EBITDA Ratio |
-0.72 |
-1.14 |
-1.43 |
-1.11 |
-0.74 |
0.03 |
| Operating Income Ratio
|
-2.34
|
-2.64
|
-2.31
|
-1.81
|
-1.08
|
-0.54
|
| Total Other
Income/Expenses Net |
$5.45 M
|
-$121,824.00
|
$9.06 M
|
-$4.73 M
|
-$13.84 M
|
-$24.84 M
|
| Income Before Tax |
-$8.16 M |
-$20.04 M |
-$8.99 M |
-$22.01 M |
-$33.16 M |
-$32.49 M |
| Income Before Tax Ratio
|
-1.4
|
-3.34
|
-1.15
|
-2.3
|
-2.13
|
-2.31
|
| Income Tax Expense |
$0.00 |
$7.00 M |
$368,660.00 |
-$1.43 M |
-$645,866.00 |
-$13,365.00 |
| Net Income |
-$8.16 M |
-$27.04 M |
-$9.36 M |
-$20.59 M |
-$32.51 M |
-$32.47 M |
| Net Income Ratio |
-1.4 |
-4.51 |
-1.2 |
-2.15 |
-2.09 |
-2.31 |
| EPS |
-6.35 |
-13.06 |
-8.59 |
-21.21 |
-190.46 |
-324.73 |
| EPS Diluted |
-6.35 |
-13.06 |
-8.59 |
-21.21 |
-190.46 |
-324.73 |
| Weighted Average Shares
Out |
$2.18 M
|
$2.07 M
|
$1.09 M
|
$970,765.00
|
$170,702.00
|
$99,999.00
|
| Weighted Average Shares
Out Diluted |
$2.18 M
|
$2.07 M
|
$1.09 M
|
$970,765.00
|
$170,702.00
|
$100,000.00
|
| Link |
|
|
|
|
|
|
